SCHEMBL3758964

SCHEMBL3758964

COC(=O)c1c(OC)ccc2nccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
POLB P06746 2/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25056111 0.81 KDM4E (0.41) MEN1KMT2AMAPK8MAPK9MAPK10
SCHEMBL3525048 0.79 TSHR (0.39) MEN1KMT2AHTTCA12CA1
SCHEMBL3521739 0.79 MEN1 (0.37) MEN1KMT2AHTTCA9KDM4E
SCHEMBL3521388 0.78 TP53 (0.40) MEN1KMT2AHTTKDM4EMAPT
SCHEMBL3520256 0.76 ALDH1A1 (0.49) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL3516702 0.76 LCK (0.40) MEN1KMT2AHTTKDM4ESMN1; SMN2
SCHEMBL1080724 0.75 QPCT (0.44) MEN1KMT2AKDM4EMAPTPOLB
SCHEMBL3753086 0.74 SMN1; SMN2 (0.52) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3521893 0.74 SMN1; SMN2 (0.52) MEN1KMT2AHTTKDM4EMAPT
SCHEMBL3519633 0.72 MEN1 (0.47) MEN1KMT2AHTTKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 MEN1 2552/4885KMT2A 300/4885MAPK8 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.